ADDISON, TEXAS - We're pleased to introduce Mrs. Denise Stamos RN, MSN, MBA, as the newest member of the Solenic Medical team, serving as Vice President of Clinical Operations. In this role, she will oversee our First-in-Humans clinical initiatives, including Feasibility and subsequent Pivotal clinical studies.
Bringing over 30 years of experience in healthcare and healthcare technology, Mrs. Stamos has a deep understanding of acute and post-acute care and regulatory processes. With a background in clinical research and nursing, she possesses a valuable combination of healthcare knowledge and business expertise.
Throughout her career, Mrs. Stamos has held leadership positions at organizations such as Curantis Solutions, Vizient, Inc., Medfusion, and Texas Health Resources. Her areas of focus have included product development, strategic planning, and market expansion.
Denise holds degrees from West Texas A&M University, where she earned both her Bachelor’s and Master of Science in Nursing, and an MBA from UT Dallas Business School.
We warmly welcome Mrs. Stamos to the Solenic Medical team, confident that her wealth of experience will enhance our dedication to innovation, quality, and transformative healthcare solutions. We eagerly anticipate the positive impact she will undoubtedly bring to our organization.
About Solenic Medical
Solenic Medical, Inc. is a medical device company developing an innovative non-invasive treatment for infected metallic implants in the body. Using technology invented at the University of Texas Southwestern, Solenic is leveraging the unique properties of alternating magnetic fields (AMF) generated by external coils to reduce, and possibly eradicate, the biofilm on the surface of metallic implants. This non-invasive, non-contact treatment addresses a major complication frequently associated with various surgeries such as knee and hip replacements, and orthopedic trauma cases requiring plates, rods, and/or nails. The technology is particularly important and timely given the rise in the aging population, longer life expectancy, and the rapid increase in the number of orthopedic procedures being performed every year. Solenic's AMF technology has been designated a Breakthrough Device by the U.S. FDA. It has the potential to completely replace the costly and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Solenic Medical, Inc. is a VIC Technology Venture Development™ portfolio company.